# Canadian Treat and Extend Analysis Trial With Ranibizumab

> **NCT02103738** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 505 (actual)

## Conditions studied

- wetAMD

## Interventions

- **OTHER:** 0.5 mg Ranibizumab intravitreal injections

## Key facts

- **NCT ID:** NCT02103738
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-08
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 505 (ACTUAL)
- **Last updated:** 2020-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02103738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02103738, "Canadian Treat and Extend Analysis Trial With Ranibizumab". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02103738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*